المؤلفون: A Roshini, Asha S. Nair, Sankar Jagadeeshan, K Sadasivan, Mathangi Ravi, Anand Krishnan, A Lakshmi, Leena Dennis Joseph, Ganesh Venkatraman, J Mavuluri, A. Subramanian, Mahak Singhal, Y R Krishnamoorthy, Suresh K. Rayala, Ganga Baskar

المصدر: IndraStra Global.

مصطلحات موضوعية: Cancer Research, Transcription, Genetic, transcription factor RelA, cell transformation, Biology, medicine.disease_cause, Mice, PAK1, promoter region, Downregulation and upregulation, fibronectin, Pancreatic cancer, Cell Line, Tumor, medicine, Transcriptional regulation, Animals, Humans, animal, genetics, human, Promoter Regions, Genetic, Molecular Biology, mouse, Kinase, Cell growth, genetic transcription, tumor cell line, gene expression regulation, medicine.disease, Fibronectins, Fibronectin, Pancreatic Neoplasms, Gene Expression Regulation, Neoplastic, Cell Transformation, Neoplastic, p21-Activated Kinases, physiology, biology.protein, Cancer research, p21 activated kinase, Carcinogenesis, metabolism, Carcinoma, Pancreatic Ductal

الوصف: Pancreatic ductal adenocarcinoma (PDAC) is the eighth largest cause of cancer-related mortality across the world, with a median 5-year survival rate of less than 3.5%. This is partly because the molecules and the molecular mechanisms that contribute to PDAC are not well understood. Our goal is to understand the role of p21-activated kinase 1 (Pak1) signaling axis in the progression of PDAC. Pak1, a serine/threonine kinase, is a well-known regulator of cytoskeletal remodeling, cell motility, cell proliferation and cell survival. Recent reports suggest that Pak1 by itself can have an oncogenic role in a wide variety of cancers. In this study, we analyzed the expression of Pak1 in human pancreatic cancer tissues and found that Pak1 levels are significantly upregulated in PDAC samples as compared with adjacent normals. Further, to study the functional role of Pak1 in pancreatic cancer model systems, we developed stable overexpression and lentiviral short hairpin RNA-mediated knockdown (KD) clones of Pak1 and studied the changes in transforming properties of the cells. We also observed that Pak1 KD clones failed to form tumors in nude mice. By adopting a quantitative PCR array-based approach, we identified fibronectin, a component of the extracellular matrix and a mesenchymal marker, as a transcriptional target of Pak1 signaling. The underlying molecular mechanism of Pak1-mediated transformation includes its nuclear import and recruitment to the fibronectin promoter via interaction with nuclear factor-κB (NF-κB)-p65 complex. To our knowledge, this is the first study illustrating Pak1-NF-κB-p65-mediated fibronectin regulation as a potent tumor-promoting mechanism in KRAS intact model.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f60f0cb57f6540cee90dfacca4dc15fTest
https://igi.indrastra.com/items/show/83249Test

المؤلفون: Akila Kesavan, Ramya Ranganathan, Yoganathan Ramia Krishnamoorthy, Ganesh Venkatraman, Suresh K. Rayala, Shruthilaya Madanmohan, Ganga Baskar, Roy Santosham, D. Ponraju

المصدر: International Journal of Nanomedicine, Vol 2012, Iss default, Pp 1043-1060 (2012)
International Journal of Nanomedicine

مصطلحات موضوعية: Medicine (General), drug dosage form comparison, apolipoprotein labeled nanop aptamer labeled nanop cisplatin, Pharmaceutical Science, heating, Medical Oncology, Drug Delivery Systems, Neoplasms, Drug Discovery, Nanobiotechnology, drug delivery system, curcumin, animal, stomach cancer, nanotechnology, peptide labeled nanop small interfering RNA, ovary cancer, methodology, General Medicine, prostate cancer, nanomedicine, Cancer treatment, unclassified drug, Drug delivery, oncology, Nanomedicine, cancer therapy, medicine.medical_specialty, magnetic nanop nanomaterial, hyperthermic therapy, nanop paclitaxel, Biophysics, Cancer therapy, folate linked nanop HER2 antibody labeled nanop liposome, review, Bioengineering, Nanotechnology, doxorubicin, nanoencapsulation, Biomaterials, R5-920, breast cancer, medicine, drug mechanism, cancer, Animals, Humans, human, Intensive care medicine, copolymer, nonhuman, patient-friendly, drug-delivery systems, business.industry, Organic Chemistry, Cancer, drug targeting, medicine.disease, drug formulation, lung cancer, cancer research, business, lung carcinoma, neoplasm

الوصف: Ramya Ranganathan1,*, Shruthilaya Madanmohan1,*, Akila Kesavan1, Ganga Baskar1, Yoganathan Ramia Krishnamoorthy2, Roy Santosham3, D Ponraju4, Suresh Kumar Rayala2, Ganesh Venkatraman1 1Department of Human Genetics, Sri Ramachandra University, Porur, 2Department of Biotechnology, Indian Institute of Technology, Madras, 3Department of Radiology and Imaging Sciences, Sri Ramachandra University, Porur, Chennai, 4Safety Engineering Division, Nuclear and Engineering Safety Group, Indira Gandhi Center for Atomic Research, Kalpakkam, India*Authors contributed equally to this workAbstract: The focus on nanotechnology in cancer treatment and diagnosis has intensified due to the serious side effects caused by anticancer agents as a result of their cytotoxic actions on normal cells. This nonspecific action of chemotherapy has awakened a need for formulations capable of definitive targeting with enhanced tumor-killing. Nanooncology, the application of nanobiotechnology to the management of cancer, is currently the most important area of nanomedicine. Currently several nanomaterial-based drug-delivery systems are in vogue and several others are in various stages of development. Tumor-targeted drug-delivery systems are envisioned as magic bullets for cancer therapy and several groups are working globally for development of robust systems.Keywords: patient-friendly, drug-delivery systems, cancer, nanomedicine

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a3491afc987e94178c55c52a05e1c2fTest
http://hdl.handle.net/11717/13896Test